StockData
Vicapsys Life Sciences, Inc. logo

Vicapsys Life Sciences, Inc. (VICP) stock

VICPOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2024, quarter ended Sep 30, 2024Last filing: 10-Q on Jan 10, 2025
$0.40+0.00 (0.00%)

Close on Oct 19, 2026Market cap $13.73MP/E –Yield –

Vicapsys Life Sciences r&d expenses

Research and development expenses are spending on new products and technology.

Vicapsys Life Sciences's R&D Expenses for the twelve months ending Sep 30, 2024 was $14.09K, down 7.7% year over year. For fiscal 2023 it was $15.27K, up 16.6% from the year before. The highest annual figure on record is $102.18K in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2023Dec 31, 2023$15.27K+16.6%
FY2022Dec 31, 2022$13.10K-26.0%
FY2021Dec 31, 2021$17.70K-82.7%
FY2020Dec 31, 2020$102.18K+3.2%
FY2019Dec 31, 2019$98.98K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2024Sep 30, 2024$3.75K+14.7%
Q2 FY2024Jun 30, 2024$10.00K+400.0%
Q1 FY2024Mar 31, 2024$344-96.6%
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$3.27K+5.5%
Q2 FY2023Jun 30, 2023$2.00K–
Q1 FY2023Mar 31, 2023$10.00K0.0%
Q4 FY2022Dec 31, 2022$0-100.0%
Q3 FY2022Sep 30, 2022$3.10K–
Q2 FY2022Jun 30, 2022$0-100.0%
Q1 FY2022Mar 31, 2022$10.00K+333.5%
Q4 FY2021Dec 31, 2021$10.46K+28.6%
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$4.94K–
Q1 FY2021Mar 31, 2021$2.31K-97.5%
Q4 FY2020Dec 31, 2020$8.13K-91.8%
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$94.05K–
Q3 FY2019Sep 30, 2019$98.98K–

More Vicapsys Life Sciences figures

See a number that looks wrong?